On 20 March 2007, orphan designation (EU/3/07/437) was granted by the European Commission to Santhera Pharmaceuticals (Deutschland) GmbH, Germany, for idebenone for the treatment of Duchenne muscular dystrophy.
The name of the sponsor changed to Santhera Pharmaceuticals (Deutschland) GmbH in September 2010.
|Disease / condition||
Treatment of Duchenne muscular dystrophy
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.